Affordable Access

Publisher Website

Biologic characterization and chemotherapeutic response of MS-2 tumor: a non-regressing mouse sarcoma derived from MSV-M-induced sarcoma

Authors
Journal
European Journal of Cancer (1965)
0014-2964
Publisher
Elsevier
Publication Date
Volume
14
Issue
5
Identifiers
DOI: 10.1016/0014-2964(78)90260-8
Disciplines
  • Biology
  • Medicine

Abstract

Abstract MS- 2 tumor produced in BALB/c mice by transplant of in vitro cultivated cells derived from a primary MSV-M tumor in mice did not show spontaneous regression but grew progressively and killed the host. The MS- 2 tumor was histologically classified as a malignant sarcoma. In syngeneic BALB/c mice, the i.m. transplanted MS- 2 tumor had a mean doubling time of 2.5 days when the tumor mass was 500 mg and 14 days when the tumor reached 4.0 g. MS- 2 tumor cells showed a high ability to metastatize (tested by bioassay). The organ mainly involved was the lung. In a small percentage of mice, metastases were also detected in spleen, liver, kidney, brain and blood. The activity of: cyclophosphamide, daunorubicin, adriamycin and 4′-epi-adriamycin on the MS- 2 tumor was evaluated. The effects on both tumor growth and pulmonary metastases were detected. In parallel, the drugs were tested on the highly immunogenic T-MSV tumor, obtained by serial. in vivo passages of the primary MSV-induced tumor. Daunorubicin did not have any therapeutic effect on the growth of MS- 2 tumor; adriamycin produced a marked delay of the tumor growth and a significant increase of the life span; cyclophosphamide produced a longer delay in tumor growth than adriamycin did, but the life span was only slightly increased. On the T-MSV tumor, daunorubicin and adriamycin reduced tumor growth and did not affect spontaneous tumor regression; cyclophosphamide reduced tumor growth but completely abolished the spontaneous regression. Adriamycin and its new derivative 4′-epi-adriamycin, given to mice in which the MS- 2 tumor had been surgically removed, inhibited the presence of tumor cells at the lung level. The MS- 2 tumor studied in parallel with the T-MSV tumor allows the comparison of drug activity on a highly or weakly immunogenic tumor. Moreover, the MS- 2 tumor is a viable model for studying the activity of chemotherapeutic drugs on lung metastases and their adjuvant effect on surgery.

There are no comments yet on this publication. Be the first to share your thoughts.